SCHEMBL301986

SCHEMBL301986

CC(C)NC(=O)c1cc(N(Cc2ccccc2)S(=O)(=O)c2cccnc2)ccc1F

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 1/20 0.51
CYP11B1 P15538 1/20 0.48
MAPT P10636 1/20 0.46
HTT P42858 2/20 0.45
LMNA P02545 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
ALDH1A1 P00352 1/20 0.45
GAA P10253 2/20 0.44
KEAP1 Q14145 2/20 0.43
NFE2L2 Q16236 2/20 0.43
MCL1 Q07820 2/20 0.43
RAB9A P51151 2/20 0.43
MMP1 P03956 2/20 0.42
MMP9 P14780 2/20 0.42
MMP13 P45452 2/20 0.42
ADAM17 P78536 2/20 0.42
NPC1 O15118 1/20 0.42
NR1I2 O75469 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL303299 0.93 NAMPT (0.48) NAMPTCYP11B1HTTLMNANPSR1
SCHEMBL18487092 0.92 NAMPT (0.54) NAMPTMAPTHTTLMNAGAA
SCHEMBL3377911 0.91 MAPT (0.54) MAPTHTTGAAMCL1NR1I2
SCHEMBL3380874 0.86 NR3C1 (0.54) MAPTHTTGAAKEAP1NFE2L2
SCHEMBL18487075 0.84 NAMPT (0.42) NAMPTCYP11B1HTTLMNANPSR1
SCHEMBL303030 0.84 GRM2 (0.54) CYP11B1MAPTHTTLMNANPSR1
SCHEMBL3380436 0.82 NR1H2 (0.45) MAPTLMNAALDH1A1MCL1
SCHEMBL302950 0.82 NR3C1 (0.55) MAPTHTTLMNAGAAKEAP1
SCHEMBL303293 0.82 GAA (0.63) MAPTHTTLMNAGAA
SCHEMBL18487096 0.81 MEN1 (0.46) MAPTALDH1A1MCL1NR1I2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2342177-B1 NOVEL POTASSIUM CHANNEL BLOCKERS JAPAN TOBACCO INC (JP) 2017-02-15 EP claimed
US-8673901-B2 Potassium channel blockers XENTION LIMITED (GB) 2014-03-18 US claimed
JP-2012500836-A 2012-01-12 JP claimed
EP-2342177-A1 NOVEL POTASSIUM CHANNEL BLOCKERS Xention Limited (GB) 2011-07-13 EP claimed
US-20100087428-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US claimed
WO-2010023448-A1 NOVEL POTASSIUM CHANNEL BLOCKERS XENTION LIMITED (GB) 2010-03-04 WO claimed
EP-2342177-B1 NOVEL POTASSIUM CHANNEL BLOCKERS JAPAN TOBACCO INC (JP) 2017-02-15 EP disclosed
US-9447033-B2 Potassium channel blockers JAPAN TOBACCO INC. (JP) 2016-09-20 US disclosed
US-20150259282-A1 Potassium Channel Blockers XENTION LIMITED (GB) 2015-09-17 US disclosed
US-8673901-B2 Potassium channel blockers XENTION LIMITED (GB) 2014-03-18 US disclosed
US-20100087428-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087428-A1 Novel Potassium Channel Blockers HCN4, SCN2B, KCNH2 NAMPT 2896/4885CYP11B1 807/4885MAPT 4874/4885
US-20150259282-A1 Potassium Channel Blockers KCNJ2, KCNH2, KCNB1 NAMPT 2799/4885CYP11B1 1322/4885MAPT 2884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.